What does Calypte Biomedical do?
Calypte Biomedical Corporation is dedicated to developing and marketing in vitro testing algorithms for improved diagnosis of HIV-1 infection, STDs, and other chronic diseases. Calypte’s current emphasis is the commercialization of our HIV-1/2 Rapid Tests, test products for the rapid detection of antibodies to HIV-1 and HIV Type 2, a second type of HIV (“HIV-2”), in oral fluid and blood samples using a lateral flow dipstick design (the “HIV-1/2 Rapid Tests”). These tests are particularly suitable for point-of-care testing in both the professional sector, such as in developing countries that lack the medical infrastructure to support laboratory based testing, and in the over-the-counter or “OTC” market. We also manufacture and distribute an HIV-1 BED Incidence EIA test (the “BED Incidence Test”) that detects HIV-1 infections that have occurred within approximately the prior 6 months and that can be used by public health agencies to identify those regions and the populations within them
